JGC
AGRX

J. Goldman & Co’s Agile Therapeutics AGRX Stock Holding History

J. Goldman & Co’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5
Closed -$6K – 351
2018
Q4 		$6K Hold
5
– – ﹤0.01% 232
2018
Q3 		$4K Sell
5
-4
-44% -$2.93K ﹤0.01% 251
2018
Q2 		$9K Sell
9
-283
-97% -$993K ﹤0.01% 341
2018
Q1 		$1.5M Buy
+292
New +$1.93M 0.06% 239
2017
Q1 		– Sell
-18
Closed -$205K – 433
2016
Q4 		$205K Sell
18
-74
-80% -$1.04M 0.01% 279
2016
Q3 		$1.29M Sell
92
-36
-28% -$514K 0.07% 221
2016
Q2 		$1.96M Sell
128
-27
-17% -$370K 0.1% 198
2016
Q1 		$1.93M Buy
+155
New +$2M 0.12% 187

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

J. Goldman & Co's AGRX Position: Q1 2019 in Review

J. Goldman & Co sold out of Agile Therapeutics (AGRX) in Q1 2019, closing a stake of 5 shares — an estimated $6K sold.

J. Goldman & Co first reported a position in AGRX in Q1 2016 and held it in 8 quarters. The position peaked at $1.96M in Q2 2016. 26 funds tracked by Wall St. Rank hold AGRX as of Q1 2019.

  • J. Goldman & Co reported no remaining Agile Therapeutics position as of Q1 2019 after selling out during the quarter.
  • J. Goldman & Co sold 5 Agile Therapeutics shares in Q1 2019, an estimated $6K.
  • J. Goldman & Co first reported a position in Agile Therapeutics in Q1 2016 and held it in 8 quarters.
  • J. Goldman & Co's Agile Therapeutics position peaked at $1.96M in Q2 2016.
  • 26 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2019.

Based on J. Goldman & Co's 13F filing for Q1 2019, filed 14 May 2019.